Peter Chang
About
Peter Chang is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology.
According to data from OpenAlex, Peter Chang has authored 151 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Pulmonary and Respiratory Medicine, 46 papers in Surgery and 20 papers in Oncology. Recurrent topics in Peter Chang's work include Prostate Cancer Diagnosis and Treatment (36 papers), Renal cell carcinoma treatment (27 papers) and Prostate Cancer Treatment and Research (26 papers). Peter Chang is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (36 papers), Renal cell carcinoma treatment (27 papers) and Prostate Cancer Treatment and Research (26 papers). Peter Chang collaborates with scholars based in United States, Canada and United Kingdom. Peter Chang's co-authors include Andrew A. Wagner, Peter Rieckmann, Kottil Rammohan, Gıancarlo Comı, Bruno Musch, Anthony Hamlett, Patrick Vermersch, Per Soelberg Sørensen, Steven J. Greenberg and Stuart D. Cook and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Neurology.
In The Last Decade
Peter Chang
140 papers receiving 4.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peter Chang United States | 34 | 1.4k | 1.4k | 1.0k | 781 | 731 | 151 | 4.5k | ||
| Raphaèle Séror France | 43 | 1.3k 1.0× | 1.9k 1.4× | 2.2k 2.2× | 725 0.9× | 2.9k 4.0× | 175 | 8.5k | ||
| Jianguang Ji Sweden | 40 | 777 0.6× | 836 0.6× | 708 0.7× | 1.1k 1.4× | 348 0.5× | 197 | 4.9k | ||
| Franz Quehenberger Austria | 34 | 629 0.5× | 1.2k 0.9× | 809 0.8× | 866 1.1× | 186 0.3× | 193 | 4.6k | ||
| Roberto Stasi Italy | 49 | 1.9k 1.4× | 1.1k 0.8× | 1.1k 1.1× | 1.1k 1.5× | 493 0.7× | 161 | 9.7k | ||
| Karin E. Smedby Sweden | 40 | 2.0k 1.5× | 654 0.5× | 672 0.6× | 2.3k 2.9× | 384 0.5× | 206 | 5.8k | ||
| Dieter Körholz Germany | 29 | 913 0.7× | 841 0.6× | 353 0.3× | 820 1.0× | 222 0.3× | 138 | 3.1k | ||
| Marc E. Horowitz United States | 41 | 698 0.5× | 1.9k 1.4× | 789 0.8× | 1.2k 1.5× | 433 0.6× | 98 | 5.9k | ||
| Jacques‐Eric Gottenberg France | 46 | 1.0k 0.8× | 520 0.4× | 1.4k 1.3× | 732 0.9× | 2.7k 3.7× | 163 | 7.1k | ||
| Kazumoto Iijima Japan | 45 | 1.4k 1.0× | 1.3k 0.9× | 698 0.7× | 326 0.4× | 543 0.7× | 499 | 9.0k | ||
| Sébastien Salas France | 31 | 722 0.5× | 1.6k 1.2× | 320 0.3× | 1.0k 1.3× | 1.3k 1.7× | 169 | 3.5k |
Countries citing papers authored by Peter Chang
Since
Specialization
Citations
This map shows the geographic impact of Peter Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Chang more than expected).
Fields of papers citing papers by Peter Chang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Peter Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Chang. The network helps show where Peter Chang may publish in the future.
Co-authorship network of co-authors of Peter Chang
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Chang. A scholar is included among the top collaborators of Peter Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Chang. Peter Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sathe, Abhishek G., Paul M. Diderichsen, Xiaohui Wang, et al.. (2025). Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR +/ HER2 − Metastatic Breast Cancer Data From the Phase 3 TROPiCS ‐02 Trial. Clinical and Translational Science. 18(7). e70291–e70291.
2.
Pallauf, Maximilian, Michael E. Rezaee, Roy Elias, et al.. (2025). Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance. British Journal of Urology. 135(5). 860–868.
3.
Chiang, Yang‐Jen, Jaewon Oh, Siew Pang Chan, et al.. (2025). Impact of mechanical pulmonary thrombectomy for intermediate-risk pulmonary embolism: Results from a prospective multicenter, multi-ethnic Asian registry. Thrombosis Research. 251. 109357–109357.
4.
Linderman, Scott W., et al.. (2025). Dynamax: A Python package for probabilistic state space modeling with JAX. The Journal of Open Source Software. 10(108). 7069–7069.
5.
Nael, Ali, et al.. (2024). Histopathology imaging and clinical data including remission status in pediatric inflammatory bowel disease. Scientific Data. 11(1). 761–761.
6.
Dodge, Laura E., et al.. (2023). Prevalence and Morbidity of Local Treatment-Related Side Effects in Metastatic Prostate Cancer Patients. Urologic Oncology Seminars and Original Investigations. 41(4). 204.e1–204.e6.
7.
Kojodjojo, Pipin, et al.. (2023). First use of large-bore suction thrombectomy for acute pulmonary embolism in Asia-Pacific: feasibility and short-term clinical outcomes. Journal of Thrombosis and Thrombolysis. 55(4). 660–666.
8.
Cheaib, Joseph, Nirmish Singla, Peter Chang, et al.. (2023). PD08-11 ACTIVE SURVEILLANCE VERSUS PRIMARY INTERVENTION FOR CLINICAL T1a KIDNEY TUMORS: TWELVE-YEAR EXPERIENCE OF THE DISSRM PROSPECTIVE COMPARATIVE STUDY. The Journal of Urology. 209(Supplement 4).
9.
Zhu, Zhu, Benjamin Vanderschelden, Sook Joung Lee, et al.. (2023). Methamphetamine use increases the risk of cerebral small vessel disease in young patients with acute ischemic stroke. Scientific Reports. 13(1). 8494–8494.
10.
Fleishman, Aaron, Ruslan Korets, Peter Chang, et al.. (2023). Conditional survival following radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology Seminars and Original Investigations. 41(10). 432.e11–432.e20.
11.
Chew, Nicholas, et al.. (2021). The allergic myocardial infarction dilemma: is it the anaphylaxis or the epinephrine?. Journal of Thrombosis and Thrombolysis. 52(3). 941–948.
12.
Trostel, Shana Y., Olga Voznesensky, Rachel Schaefer, et al.. (2019). Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precision Oncology. 3(3). 1–13.
13.
McKay, Rana R., Huihui Ye, Wanling Xie, et al.. (2019). Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology. 37(11). 923–931.
14.
Srivastava, Arnav, Hiten D. Patel, Mohit Gupta, et al.. (2019). The incidence, predictors, and survival of disappearing small renal masses on active surveillance. Urologic Oncology Seminars and Original Investigations. 38(2). 42.e1–42.e6.
15.
Sanda, Martin G., Olatz Garín, Peter Chang, et al.. (2019). A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian journal of urology. 7(2). 161–169.
16.
Gupta, Mohit, Ridwan Alam, Hiten D. Patel, et al.. (2018). Use of delayed intervention for small renal masses initially managed with active surveillance. Urologic Oncology Seminars and Original Investigations. 37(1). 18–25.
17.
McKay, Rana R., Bruce Montgomery, Wanling Xie, et al.. (2017). Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer and Prostatic Diseases. 21(3). 364–372.
18.
Kocher, Neil J., Évanguelos Xylinas, Peter Chang, et al.. (2017). MP67-18 THE COMPREHENSIVE COMPLICATION INDEX (CCI) IS SUPERIOR TO THE CLAVIEN-DINDO GRADING SYSTEM IN PREDICTING LENGTH OF STAY AND HOSPITAL READMISSION FOLLOWING RADICAL NEPHROURETERECTOMY. The Journal of Urology. 197(4S).
19.
Carneiro, Ariê, et al.. (2014). Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology. 32(4_suppl). 40–40.
20.
Vermersch, Patrick, Giacomo P. Comi, Gavin Giovannoni, et al.. (2011). Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study. UCL Discovery (University College London).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Raphaèle Séror Breakdown of academic impact, for papers by Jianguang Ji Breakdown of academic impact, for papers by Franz Quehenberger Breakdown of academic impact, for papers by Roberto Stasi Breakdown of academic impact, for papers by Karin E. Smedby Breakdown of academic impact, for papers by Dieter Körholz Breakdown of academic impact, for papers by Marc E. Horowitz Breakdown of academic impact, for papers by Jacques‐Eric Gottenberg Breakdown of academic impact, for papers by Kazumoto Iijima Breakdown of academic impact, for papers by Sébastien Salas